Iron deficiency anemia: diagnosis and management
Iron deficiency anemia: diagnosis and management
复制标题
DOI：
10.1097/mog.0b013e32831ef1cd
复制
发表时间：
2009-03-01
影响因子：
2.5
通讯作者：
Clark, Susan F.
中科院分区：
文献类型：
--
作者：
Clark, Susan F.
综述目的缺铁性贫血(IDA)仍然是世界范围内普遍存在的问题。这篇综述的主要焦点是对过去18个月发表的描述这种流行疾病的诊断和治疗策略的文章进行评论。最近的发现医学界在确定诊断和治疗IDA的最佳方法时仍然缺乏共识。目前的诊断建议围绕着当前生物标记物的有效性和实用性，如可溶性转铁蛋白受体浓度和其他，以及可能包括内窥镜检查的基于原因的诊断。对缺铁性贫血的治疗是基于补充和有效的病因治疗。口服和肠外低分子量铁制剂的进展扩大和改进了IDA的治疗方式。自从引入低分子量静脉补铁与高分子量静脉补铁相比，与肠外补铁相关的严重不良事件已经减少。摘要诊断和治疗IDA的最佳实践指南应该包括设计一种包含多个生物标志物和基于病因的诊断的算法，这将为IDA的治疗提供指导，并将IDA与慢性病贫血区分开来。
Purpose of reviewIron deficiency anemia (IDA) still remains universally problematic worldwide. The primary focus of this review is to critique articles published over the past 18 months that describe strategies for the diagnosis and management of this prevalent condition.Recent findingsThe medical community continues to lack consensus when identifying the optimal approach for the diagnosis and management of IDA. Current diagnostic recommendations revolve around the validity and practicality of current biomarkers such as soluble transferrin-receptor concentrations and others, and cause-based diagnostics that potentially include endoscopy. Management of IDA is based on supplementation combined with effective etiological treatment. Advances in oral and parenteral low-molecular-weight iron preparations has expanded and improved treatment modalities for IDA. Since the introduction of low versus high-molecular-weight intravenous iron administration, there have been fewer serious adverse events associated with parenteral iron preparations.SummaryBest practice guidelines for diagnosing and managing IDA should include the design of an algorithm that is inclusive of multiple biomarkers and cause-based diagnostics, which will provide direction in managing IDA, and distinguish between IDA from the anemia of chronic disease.